Shandong Xinhua Pharmaceutical Company Limited (HKG: 0719)

Shandong Xinhua Pharmaceutical Company Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	8,017	7,956	7,295	6,360	5,949	5,540
Other Revenue	143.56	144.78	207.82	200.54	56.85	66.37
Revenue	8,161	8,101	7,503	6,560	6,006	5,606
Revenue Growth (YoY)	-4.11%	7.97%	14.37%	9.23%	7.13%	6.89%
Cost of Revenue	6,048	5,779	5,515	4,824	4,244	3,817
Gross Profit	2,113	2,321	1,988	1,736	1,762	1,789
Selling, General & Admin	1,141	1,287	1,106	929.12	943.96	1,105
Research & Development	426.82	419.24	345.66	341.37	298.35	235.4
Other Operating Expenses	57.36	92.18	65.31	59.27	60.28	58.19
Operating Expenses	1,640	1,809	1,522	1,332	1,303	1,399
Operating Income	473.52	512.15	465.87	403.67	458.77	390.33
Interest Expense	-37.53	-41.15	-49.71	-53.1	-59.76	-55.32
Interest & Investment Income	20.96	21.88	18.83	16.79	11.58	8.76
Currency Exchange Gain (Loss)	14.93	15.42	10.53	-4.18	-24.78	8.11
Other Non Operating Income (Expenses)	-4.69	-2.72	-3.38	-2.45	-4.46	-4.46
EBT Excluding Unusual Items	467.21	505.59	442.15	360.72	381.35	347.43
Gain (Loss) on Sale of Assets	8.7	8.73	5.54	2.07	2.49	0.84
Asset Writedown	-10.48	-10.29	-2.61	-1.88	-4.43	-2.65
Other Unusual Items	38.68	28.65	26.7	60.32	32.23	35.78
Pretax Income	504.1	532.69	471.77	421.23	411.64	381.39
Income Tax Expense	0.91	26.58	45.66	59.16	64.52	58.28
Earnings From Continuing Operations	503.19	506.11	426.11	362.07	347.11	323.12
Minority Interest in Earnings	-11.08	-9.59	-15.05	-13.53	-22.25	-23.15
Net Income	492.11	496.51	411.06	348.55	324.86	299.97
Net Income to Common	492.11	496.51	411.06	348.55	324.86	299.97
Net Income Growth	1.16%	20.79%	17.94%	7.29%	8.30%	17.49%
Shares Outstanding (Basic)	678	674	661	627	622	622
Shares Outstanding (Diluted)	691	692	671	627	627	622
Shares Change (YoY)	0.44%	3.20%	6.92%	-0.02%	0.86%	-0.14%
EPS (Basic)	0.73	0.74	0.62	0.56	0.52	0.48
EPS (Diluted)	0.71	0.72	0.61	0.56	0.52	0.48
EPS Growth	1.35%	18.03%	9.75%	6.89%	8.33%	17.07%
Free Cash Flow	20.17	-59.85	513.48	9.89	140	-18.24
Free Cash Flow Per Share	0.03	-0.09	0.77	0.02	0.22	-0.03
Dividend Per Share	0.275	0.250	0.200	0.150	0.150	0.120
Dividend Growth	37.50%	25.00%	33.33%	0%	25.00%	20.00%
Gross Margin	25.89%	28.66%	26.50%	26.46%	29.33%	31.92%
Operating Margin	5.80%	6.32%	6.21%	6.15%	7.64%	6.96%
Profit Margin	6.03%	6.13%	5.48%	5.31%	5.41%	5.35%
Free Cash Flow Margin	0.25%	-0.74%	6.84%	0.15%	2.33%	-0.33%
EBITDA	992.82	1,023	952.48	840.2	842.97	734.07
EBITDA Margin	12.17%	12.63%	12.69%	12.81%	14.04%	13.09%
D&A For EBITDA	519.3	511.23	486.61	436.53	384.2	343.74
EBIT	473.52	512.15	465.87	403.67	458.77	390.33
EBIT Margin	5.80%	6.32%	6.21%	6.15%	7.64%	6.96%
Effective Tax Rate	0.18%	4.99%	9.68%	14.04%	15.68%	15.28%
Revenue as Reported	8,161	8,101	7,503	-	6,006	5,606
Advertising Expenses	-	8.95	8.18	11.33	12.84	14.31

Source: S&P Capital IQ. Standard template. Financial Sources.